Literature DB >> 2942851

[Immunological disorders of coagulation in habitual abortion. Prospective study].

P Edelman, E Verdy, A M Rouquette, D Cornet, A Combrisson, J Barrat, J Chavinie, J Salat Baroux, C Sureau.   

Abstract

The physiopathological role of antithromboplastin-type circulating anticoagulants in habitual abortion may be envisaged since the presence of antithromboplastin has been reported in most studies on women at high risk of abortion. To avoid a possible statistical bias, we conducted a prospective study in a sufficiently large group of women with habitual abortion (n = 99) compared with a control group of women with normal fecundity (n = 50). In addition, all women were investigated for lupus symptoms. The circulating antibody was detected by the diluted thromboplastin time and activated cephalin time methods. The results were considered positive when the patient/control diluted thromboplastin time ratio was 1.2 and/or when the increase in activated cephalin time was not corrected by a control plasma. In the patients' group, 10 women (10%) had an anti-thromboplastin type circulating anticoagulant, whereas no circulating anticoagulant could be detected in the control group. Three women with circulating anticoagulant had signs of systemic lupus erythematosus. None of the patients presented with Soulier-Boffa syndrome. These data have established a significant correlation between habitual abortion and circulating anticoagulant whilst avoiding statistical bias. Our results suggest that women with idiopathic habitual abortion should be subjected to systematic immunological exploration and that a small number of them should be followed attentively.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2942851

Source DB:  PubMed          Journal:  Presse Med        ISSN: 0755-4982            Impact factor:   1.228


  1 in total

1.  Recurrent fetal loss and antiphospholipid antibodies: clinical and therapeutic aspects.

Authors:  O Blétry; A M Piette
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.